Tirzepatide Overview Tirzepatide is a novel dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It represents a breakthrough in metabolic disease treatment by simultaneously targeting two incretin hormones. Mechanism of Action - Activates GLP-1 receptors: Reduces appetite, slows gastric emptying, enhances insulin secretion - Activates GIP receptors: Improves insulin sensitivity, amplifies metabolic effects - Dual synergy: Combined action produces superior metabolic outcomes compared to single agonists Key Benefits Weight Management - Achieves 15-22.5% body weight reduction in clinical trials - Superior efficacy vs. Semaglutide and other GLP-1 monotherapies - Sustained weight loss with long-term use Glycemic Control - Significantly reduces HbA1c levels (up to 2.4% reduction) - Improves fasting and postprandial glucose - Low risk of hypoglycemia Cardiometabolic Health - Reduces cardiovascular risk factors - Improves lipid profile (LDL, triglycerides) - Decreases blood pressure - Potential cardiovascular protection (ongoing trials) Additional Benefits - Improves fatty liver disease (NAFLD/NASH) - Enhances insulin sensitivity in peripheral tissues - May benefit sleep apnea and physical function Administration - Subcutaneous injection, once weekly - Dose escalation: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg - Titrate based on tolerance and treatment goals Common Side Effects - Nausea, vomiting, diarrhea (dose-dependent, usually transient) - Decreased appetite - Injection site reactions - Rare: pancreatitis, gallbladder issues, thyroid C-cell tumors (rodent studies) Approved Indications - Type 2 Diabetes (Mounjaro®) - Chronic Weight Management (Zepbound®) - Off-label use for obesity-related comorbidities Clinical Significance Tirzepatide represents the next generation of incretin therapy, offering unprecedented efficacy for weight loss and metabolic control. Its dual mechanism addresses multiple pathophysiological defects in obesity and diabetes simultaneously.